Burning Rock Biotech Limited provided revenue guidance for the fiscal year 2022. For the year, the company expects revenue of approximately RMB 620 million (USD 92.6 million) for now, and would like to highlight the risks of further Covid related impact in the second half of 2022 which is beyond the Company's control and inherently difficult to forecast.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.81 USD | -5.90% | -2.98% | -16.02% |
04-02 | Earnings Flash (BNR.L) BURNING ROCK BIOTECH Posts FY23 Revenue $75.7M | MT |
04-02 | Earnings Flash (BNR.L) BURNING ROCK BIOTECH Posts FY23 Loss $-0.90 | MT |
1st Jan change | Capi. | |
---|---|---|
-16.02% | 85.15M | |
-17.05% | 8.55B | |
+68.18% | 4.24B | |
-1.63% | 2.53B | |
-9.63% | 2.44B | |
-38.23% | 2.35B | |
-7.97% | 1.89B | |
-17.13% | 1.55B | |
-39.48% | 1.23B | |
+9.68% | 1.13B |
- Stock Market
- Equities
- BNR Stock
- News Burning Rock Biotech Limited
- Burning Rock Biotech Limited Provides Revenue Guidance for the Fiscal Year 2022